This Week's Poll

At the recent BioPartner Forum it was stated the internal market is insufficient for a UK Life Science company to develop a technology, product or service at a rate that will return investor value. Do you

Supported by Medilink UK

Funding for start-ups - Andrew Ives of - Advanced Therapeutic Materials - 10:52:48am Feb-12th

Funding for start-up companies with innovations past the concept stage but some way from commercial reward, commonly called ‘the valley of death’, is still sparse. Funding for pure research is readily available. Funding for expansion of an established commercial entity with a sound business plan and track record is relatively easy to find but the bit in the middle is where we all are losing valuable initiatives. Even the VC community is loath to invest, or if they do, they will stifle the creative spark in their quest for a quick return.

Agree/Disagree + add comment
Thumbs Up1 person agrees with this

Trevor Lewis of - Medical Device Consultancy - 18:35:24pm Feb-18th

It is important even for early stage companies to get some early proof the device will deliver what customers want and they will pay for it. It is important to have a user / clinical board or focus group to help reinforce this. Letters of intent are helpful, early orders even better!

 
 
t